Long-acting porcine interferon as well as preparation method and application thereof
Through the expression strategy of the core binding region of the fusion protein GBPA-interferon 2A and ProteinAProteinG antibody, the problems of short action time and poor activity effect of antiviral drugs are solved, and the efficient expression and stability of long-acting sustained-release interferons are achieved, and effective prevention is achieved. and treat viral infections such as pig blue ear virus.
Patent Information
- Application Number
- CN202410968044.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-08
AI Technical Summary
The existing antiviral drugs have a short time to act in animals, require continuous injection and have poor activity effect.
The fusion protein GBPA-interferon 2A is used, which is fused by protein A and protein B. It forms a fusion protein through ligation peptide linkage. It is used for a long-term sustained-release interferon expression strategy. It is expressed in E. coli in combination with the core binding region of Protein AProteinG antibody. Form high-purity, long-acting interferon.
It realizes the long-term sustained release function, improves the stability and therapeutic activity of interferon, reduces the frequency of medication and adverse reactions, has high therapeutic activity, and can effectively prevent and resist viral infections such as pig blue ear virus.
Smart Images

Figure SMS_2 
Figure SMS_3 
Figure SMS_4
Abstract
Description
Technical Field
[0001] The present application belongs to the technical field of biological products, and specifically relates to a long-acting porcine interferon and a preparation method and application thereof. Background Art
[0002] (Interferon, as the most important immune factor against viral infection, is a group of low-molecular glycoproteins with similar structures and functions produced by host cells through antiviral responses when the body is infected with viruses. In 1957, two British scientists discovered during influenza virus experiments that after the inactivated influenza virus was injected into chicken embryos, a substance with the effect of "interfering" with influenza virus infection would be produced in the chicken embryo cell membrane. One of the scientists, Isaacs, called this substance "interferon", or interferon. Subsequent studies have confirmed that after the body's cells are invaded by viruses, the virus induces the expression of interferon genes in the cells to produce interferon to affect viral replication, that is, to activate the body's defense system against viral infection. According to the different primary structures of interferon proteins, they can be divided into three different types: α, β, and γ, which are produced by white blood cells, fibroblasts, and immune lymphocytes, respectively, and have antiviral, anti-cell division and immunomodulatory activities, respectively. At present, interferon-α is mainly used in clinical antiviral treatment.
[0003] Under normal circumstances, the interferon gene in the chromosomal DNA of the host cell is controlled by the inhibitory protein and is in a dormant state. When infected by a virus or stimulated by an interferon inducer, the cell produces a specific factor that inactivates the inhibitory protein, allowing the interferon gene inhibition to be released. In the ribosomes in the cell, the specific interferon mRNA generated by the interferon gene can guide the synthesis of interferon protein and release the protein outside the cell. The antiviral effect of interferon-α is mainly through the binding of interferon to the interferon receptors on the cell membrane of the virus-infected cell. Interferon has a high affinity for these receptors, and the number expressed on each cell can reach 500-20,000. After binding to the receptor, interferon activates the antiviral protein gene in the infected cell, generates antiviral protein mRNA, and induces a variety of antiviral proteins (AVP). Such AVP can cut off the virus mRNA, inhibit the translation of viral proteins, inhibit the penetration, uncoating and assembly of the virus, and ultimately inhibit the replication of the virus. There are three main types of such AVPs: ① 2'-5' oligoadenylate synthetase (2'-5'-AS): 2'-5'-AS is a dsRNA-dependent enzyme. After the activation of viral dsRNA, it promotes the polymerization of ATP into 2'-5'-oligoadenylate, which in turn activates the nuclease to hydrolyze the viral protein mRNA, blocking the transcription of viral mRNA, thereby inhibiting the synthesis of viral proteins; ② After the protein kinase interferon binds to the receptor on the cell membrane infected with the virus, the interferon response gene is activated, followed by the activation of tyrosine protein kinase (JAKs), which can phosphorylate the α subunit of the initiation factor for viral protein synthesis, thereby blocking the initiation of viral protein synthesis; ③ Phosphodiesterase can remove the pCpCpA end of tRNA, thereby inhibiting the translation of viral proteins and the expression of viral proteins.
[0004] Interferon-α is an effective inducer of MHC-1 protein exposure. It enhances the expression of animal leukocyte antigen (HLA) on the cell membrane, making it easier for immune-active cells such as TC cells to recognize and kill cells infected with hepatitis virus. It can also regulate the levels of interleukin 1 (IL-1), interleukin 2 (IL-2) and tumor necrosis factor (TNF) through the cytokine network, promote the proliferation of cytotoxic T lymphocytes (CTL), and activate the immune activity of immune-active cells such as NK cells, T cells and macrophages, thereby killing hepatitis virus-infected liver cells and clearing the virus. It is precisely because of this immune activity of interferon that CTL attacks target cells and clears viruses by recognizing HLA-1 molecules. However, in the state of chronic viral infection, the terminal protein of viral polymerase can reduce the antiviral activity of interferon, reduce HLA expression, lymphocyte expression, and IFNγ. In addition, viral mutations can also escape the body's immune response. All these factors lead to the virus carrier's own interferon deficiency and tolerance state, thus requiring large doses of exogenous interferon supplementation therapy, which requires the in vitro expression of interferon.
[0005] Recombinant animal interferon-α is a high-purity (>99%) and high-activity (1mg>108) preparation. The preparation is obtained by cloning the interferon-α gene from animal leukocytes and connecting it to a bacterial plasmid vector (the liquid can be a yeast expression vector, a mammalian cell expression vector, and a baculovirus vector) through recombinant gene technology, and then transferring it into Escherichia coli to express interferon, and then obtaining it through production and purification technology. Recombinant animal interferon-α has the same molecular structure and biological effect as the natural type, and can be divided into IFNα-2a, IFNα-1b and 2b according to the difference in individual amino acids. Their antiviral effects are roughly the same. At present, the commonly used interferon preparations in China are of two types: extraction and recombinant expression.
[0006] Pegylated interferon (PEG for short) is an inactive hydrophilic compound. Polyethylene glycol is installed on active protein molecules through biopharmaceutical technology, thereby changing its activity, making its molecular weight larger and its absorption slower. Moreover, due to the protection of polyethylene glycol molecules, the drug has fewer opportunities to contact with proteases and is metabolized more slowly, so that the drug concentration in the blood is more stable and the half-life is longer. Not only will the drug concentration not fluctuate, but the medication interval can be extended, making medication more convenient and the efficacy more stable. Pegylated interferon (also known as PEG interferon) not only maintains the drug concentration at a stable level, but also significantly extends the medication cycle due to slower clearance, and maintains the blood drug concentration at a relatively ideal level, avoiding the large concentration fluctuations after the use of ordinary interferon, thereby greatly improving the therapeutic effect. Since the medication interval can be extended from 3 times a week to once a week, the drug compliance of animals can also be significantly improved. On the other hand, in addition to interferon, due to the protective effect of polyethylene glycol, the direct contact between interferon and immune cells is reduced, the immunogenicity is reduced, and the adverse reactions are less. In terms of production technology, pegylated interferon is divided into two categories according to the size of the molecular weight of polyethylene glycol: one is pegylated interferon, whose polyethylene glycol molecule is relatively small, only 12kDa; the second is pegylated interferon, whose polyethylene glycol molecule is relatively large, with a molecular weight of 40kDa. Of these two types of pegylated interferons, the latter has a better protective effect on interferon due to its larger polyethylene glycol molecule, so its blood drug concentration is more stable, the half-life is longer, and its drug distribution is more concentrated (mainly concentrated in the blood and liver), while the body weight of adult animals can vary greatly, but the difference in blood volume is very small. Therefore, large-molecule pegylated interferon-α2a does not need to be administered according to body weight. However, small-molecule pegylated interferon must be administered according to body weight because of its wider distribution range (including muscle and fat). This technology has defects in practical application.
[0007] At present, about 70-80% of antibody purification uses Protein A and Protein G affinity chromatography. Protein A is derived from a strain of Staphylococcus aureus. It contains 5 domains that can specifically bind to the Fc segment of antibody IgG molecules. Protein A is coupled to an agarose matrix as an affinity ligand and can specifically bind to antibody molecules in the sample, while other impurities flow through. It has extremely high selectivity and can achieve a purity of more than 95% in one-step affinity chromatography. One protein A molecule can bind to at least 2 IgGs. Protein A can also bind to other immunoglobulins, such as for the purification of IgA and IgM of certain species. Protein G is a cell surface protein derived from the G group of Streptococci. It is a type III Fc receptor that binds to the Fc segment of antibodies through a non-immune mechanism similar to that of protein A. Like protein A, protein G can specifically bind to the Fc region of IgG. The difference is that Protein G Sepharose can bind more types of IgG more widely and more strongly, such as polyclonal IgG and animal IgG, and has a lower serum protein binding level, higher purity, and relatively lower ligand shedding. In addition, protein G can also bind to the Fab and F(ab')2 segments of certain antibodies. Summary of the invention
[0008] The technical problem to be solved by the present application is: how to solve the defects that the antiviral drugs for preventing animals have a short action time in animals, need to be injected continuously and have poor activity effect.
[0009] In order to solve the above technical problems, the present application provides a protein, which is a fusion protein GBPA-interferon 2A, and the fusion protein GBPA-interferon 2A is formed by the fusion of protein A and protein B.
[0010] The protein A may be any one of the following A1)-A3):
[0011] A1), a protein having an amino acid sequence of positions 1 to 117 of SEQ ID No. 2;
[0012] A2) A protein obtained by substitution and / or deletion and / or addition of amino acid residues in the amino acid sequence shown in A1), which has more than 80% identity with the protein shown in A1) and is related to the antibody binding core protein GBGA;
[0013] A3), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A1) or A2);
[0014] The protein B may be any one of the following A4)-A6):
[0015] A4), a protein having an amino acid sequence of positions 133-297 of SEQ ID No. 2;
[0016] A5) A protein obtained by substitution and / or deletion and / or addition of amino acid residues in the amino acid sequence shown in A4), which has more than 80% identity with the protein shown in A1) and is related to porcine interferon;
[0017] A6), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A5) or A6).
[0018] Furthermore, the protein A is an antibody-bound core protein GBGA, and the protein B is porcine interferon.
[0019] The protein A and the protein B can be connected via a connecting peptide to form a fusion protein.
[0020] The protein A and the protein B can be connected via a connecting peptide, specifically: the last amino acid residue of the protein A (i.e., the 117th amino acid residue of SEQ ID No. 2) is connected to the first amino acid residue of the connecting peptide, and the last amino acid residue of the connecting peptide is connected to the first amino acid residue of the protein B (i.e., the 133rd amino acid residue of SEQ ID No. 2).
[0021] Furthermore, the connecting peptide may be a GS connecting peptide.
[0022] In some embodiments of the present application, the amino acid sequence of the GS connecting peptide is 118-132 of SEQ ID No. 2. The first amino acid residue of the GS connecting peptide is the 118th amino acid residue of SEQ ID No. 2, and the last amino acid residue of the GS connecting peptide is the 132nd amino acid residue of SEQ ID No. 2.
[0023] The above connection can be achieved by forming a peptide bond through dehydration condensation of two amino acid residues.
[0024] Furthermore, the fusion protein GBPA-interferon 2A may be any one of the following A7)-A9):
[0025] A7), a protein having an amino acid sequence of SEQ ID No. 2;
[0026] A protein related to porcine interferon obtained by substitution and / or deletion and / or addition of amino acid residues in the amino acid sequences shown in A8) and A7) and having more than 80% identity with the protein shown in A1);
[0027] A9) and a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A7) or A8).
[0028] The above proteins can be artificially synthesized, or their encoding genes can be synthesized first and then expressed biologically.
[0029] The protein tag refers to a polypeptide or protein that is fused and expressed with the target protein using DNA in vitro recombination technology to facilitate the expression, detection, tracing and / or purification of the target protein. The protein tag can be a Flag protein tag, a His protein tag, an MBP protein tag, an HA protein tag, a myc protein tag, a GST protein tag and / or a SUMO protein tag, etc.
[0030] The present application also provides a nucleic acid molecule, wherein the nucleic acid molecule is a nucleic acid molecule encoding the fusion protein GBPA-interferon 2A,
[0031] The nucleic acid molecule encoding the fusion protein GBPA-interferon 2A is any one of the following g1)-g3),
[0032] g1), the coding sequence of the coding strand is the DNA molecule shown in positions 5076-5987 of SEQ ID No.1;
[0033] g2), the nucleotide sequence of the coding strand is the DNA molecule shown in positions 5076-5987 of SEQ ID No.1;
[0034] g3) A DNA molecule that has 80% or more identity with the nucleotide sequence defined in g1) or g2) and encodes the above-mentioned fusion protein GBPA-interferon 2A.
[0035] The present application also provides an expression cassette, wherein the expression cassette contains the above-mentioned nucleic acid molecule.
[0036] The present application also provides a recombinant vector, which contains the above-mentioned nucleic acid molecule or the above-mentioned expression cassette.
[0037] The present application also provides a recombinant microorganism, wherein the recombinant microorganism contains the above-mentioned nucleic acid molecule, the above-mentioned expression cassette or the above-mentioned recombinant vector.
[0038] The present application also provides a recombinant transgenic cell line, wherein the recombinant transgenic cell line contains the above-mentioned nucleic acid molecule, the above-mentioned expression cassette or the above-mentioned recombinant vector.
[0039] The present application also provides a drug comprising the above protein, which can be used to prevent and / or treat viral diseases in pigs.
[0040] The present application also provides a method for preparing the above protein, comprising: expressing the coding gene of the above fusion protein GBPA-interferon 2A in biological cells to obtain the protein; the organism is a microorganism, a plant or a non-human animal.
[0041] The present application also provides an application, which is any of the following:
[0042] P1), use of the above protein in the preparation of drugs for preventing and / or treating porcine viral diseases or antiviral drugs or antiviral infection drugs;
[0043] P2) Use of the above nucleic acid molecules in the preparation of drugs for preventing and / or treating porcine viral diseases or antiviral drugs or antiviral infection drugs;
[0044] P3) Use of the above expression cassette in the preparation of drugs for preventing and / or treating porcine viral diseases or antiviral drugs or antiviral infection drugs;
[0045] P4) Use of the above-mentioned recombinant vector in the preparation of drugs for preventing and / or treating porcine viral diseases or antiviral drugs or antiviral infection drugs;
[0046] P5) Use of the above-mentioned recombinant microorganism in the preparation of drugs for preventing and / or treating porcine viral diseases or antiviral drugs or antiviral infection drugs;
[0047] P6) Use of the above-mentioned recombinant transgenic cell line in the preparation of drugs for preventing and / or treating porcine viral diseases or antiviral drugs or antiviral infection drugs.
[0048] Furthermore, the porcine viral disease may be porcine reproductive and respiratory syndrome (PRRS, commonly known as blue ear disease), which is a disease caused by porcine reproductive and respiratory syndrome virus (PRRSV).
[0049] Furthermore, the antiviral drug may specifically be a drug against porcine reproductive and respiratory syndrome virus.
[0050] Furthermore, the anti-viral infection drug may specifically be a drug for resisting porcine reproductive and respiratory syndrome virus infection.
[0051] In the present application, identity refers to the identity of an amino acid sequence or a nucleotide sequence, and the identity of an amino acid sequence can be determined using a homology search site on the Internet, such as the BLAST page on the NCBI homepage website. For example, in Advanced BLAST 2.1, by using blastp as a program, setting the Expect value to 10, setting all Filters to OFF, using BLOSUM62 as a Matrix, setting the Gap existence cost, Per residue gap cost and Lambda ratio to 11, 1 and 0.85 (default values) respectively, and searching for the identity of a pair of amino acid sequences for calculation, the identity value (%) can be obtained.
[0052] In the present application, the above 80% identity can be at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity.
[0053] A stable, long-term and efficient interferon expression strategy can achieve long-term sustained release function; it can also be combined with other FC antigens to make multi-valent and multi-valent drugs. The specific route is that we use the long-term interferon expression strategy of E. coli expression technology to fully utilize the advantages of some of the above proteins, which can achieve long-term sustained release function; it can also be combined with other FC antigens to make multi-valent and multi-valent drugs. The specific route is that we use the long-term interferon expression technology of E. coli, 1 at the N-terminus of interferon A2a protein, fused to the protein A protein G antibody core binding region, placed in the prokaryotic promoter in E. coli to express the fusion protein. The fusion protein can be directly injected into animals after purification to remove endotoxins. Here, we invented that the long-term interferon candidate protein has high therapeutic activity in pigs and can resist the animal's response to viruses such as porcine diarrhea and pseudorabies. Our research results show that animals carrying protein A protein G interferon have the potential to effectively prevent and resist viruses. At the same time, the stability of this long-term interferon at room temperature in liquids will greatly save transportation costs by eliminating the cold chain.
[0054] The method for constructing GBPAVP1-interferon 2A fusion protein co-expressed in Escherichia coli. The strain obtained in the present application can express GBPAVP1-interferon 2A fusion protein, which has a high expression of fusion protein. The fusion protein obtained by purifying the strain after the inclusion body washing and denaturation renaturation can reach 95% purity. The protein activity can reach 10×10 9 IU / mL. After verification using the porcine epidemic diarrhea virus attack model, it can be determined that the interferon can protect pigs from epidemic diarrhea infection. The protein can be used for the prevention and protection of pig animal viruses to reduce the losses caused by the virus harming pigs.
[0055] Among them, SEQ ID No.1 in the sequence list is composed of positions 5076-5987 in the vector, encoding the protein shown in SEQ ID No.2 in the sequence list,
[0056] The nucleic acid molecules encoding the recombinant fusion protein GBPA-interferon 2A can be easily mutated by known directed evolution and point mutation methods by a person skilled in the art. The nucleotide sequences modified by animal processing are all derived from the nucleotide sequences of the present application and are equivalent to the sequences of the present application, and have 75% or higher identity with the nucleotide sequences of the nucleic acid molecules encoding the recombinant fusion protein GBPA-interferon 2A protein separated from the present application and encode the recombinant fusion protein GBPA-interferon 2A protein.
[0057] The term "coding sequence" means a polynucleotide of the amino acid sequence of a polypeptide. The boundaries of the coding sequence are usually determined by an open reading frame, which begins with a start codon such as ATG, GTG or TTG and ends with a stop codon such as TAA, TAG or TGA. The coding sequence can be genomic DNA, cDNA, synthetic DNA or a combination thereof.
[0058] The term "expression" includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.
[0059] The expression cassette in the above-mentioned biological material refers to a DNA capable of expressing a recombinant fusion GBPA-interferon 2A protein in a recombinant cell. The DNA may include not only a promoter for initiating the transcription of the GBPA-interferon 2A protein gene, but also a terminator for terminating the transcription of the GBPA-interferon 2A protein gene. Further, the expression cassette may also include an enhancer sequence. The recombinant expression vector of the nucleic acid molecule containing the recombinant fusion protein GBPA-interferon 2A protein gene is specifically a recombinant expression vector obtained by inserting the GBPA-interferon 2A gene into the multiple cloning site of the vector PET30. The recombinant microorganism is specifically Escherichia coli, and may also be other expression systems such as yeast, bacteria, algae or plants. Mammalian cells may specifically be 293 or CHO cells.
[0060] Another object of the present application is to provide the use of the above protein as a drug for treating diseases caused by porcine reproductive and respiratory syndrome virus (PRRSV), porcine circovirus and / or porcine epidemic diarrhea virus. The application may include disease diagnosis and treatment.
[0061] The term "recombinant vector" means a linear or circular DNA molecule comprising a polynucleotide encoding a polypeptide, and the polynucleotide is operably connected to a regulatory sequence provided for its expression. The recombinant vector comprises a polynucleotide of the present application, which is connected to one or more regulatory sequences, such as a promoter and transcription and translation termination signals, and the regulatory sequence directs the production of the polypeptide in an expression host. A variety of nucleotides and regulatory sequences can be combined together to produce a recombinant vector, and the recombinant vector can include one or more convenient restriction sites to allow the insertion or replacement of the polynucleotide encoding the polypeptide at these sites. Alternatively, the polynucleotide can be expressed by inserting a nucleic acid construct or polynucleotide comprising the polynucleotide in a suitable vector for expression. In the process of preparing the expression vector, the coding sequence is placed in a vector, so that the coding sequence is operably connected to a suitable regulatory sequence for expression. The recombinant vector can be any vector (e.g., a plasmid or a virus) that can conveniently carry out a recombinant DNA step and can produce expression of the polynucleotide. The choice of the vector will generally depend on the compatibility of the vector with the recombinant cell into which the vector will be introduced. The vector can be a linear or closed circular plasmid, or it can be an autonomously replicating vector. That is, a vector that exists as an extrachromosomal entity, whose replication is independent of chromosomal replication, for example, a plasmid, an extrachromosomal element, a minichromosome, or an animal chromosome. The vector may contain any means for ensuring self-replication; alternatively, the vector may be integrated into the genome when introduced into a recombinant cell and replicated together with the chromosome into which the vector has been integrated. In addition, a single vector, a plasmid, two or more vectors or plasmids that together contain the complete DNA to be introduced into the genome of a recombinant cell, or a transposon may be used.
[0062] The vector preferably contains one or more selective markers, which can simply select cells that have been transformed, transfected, transduced, etc. The vector preferably contains elements that allow the vector to be integrated into the recombinant cell genome or the vector to replicate autonomously in the cell independently of the genome. In order to be integrated into the recombinant cell genome, the vector can rely on a polynucleotide sequence encoding a polypeptide or any other vector element for homologous or non-homologous recombination integration into the genome. Alternatively, the vector can be integrated into the precise position of the host cell genome chromosome by guiding homologous recombination with the help of additional polynucleotides. In order to increase the possibility of integration at a precise position, the integration element should contain a sufficient number of nucleic acids, such as 100 to 10,000 base pairs, 400 to 10,000 base pairs or 800 to 10,000 base pairs, which have a high degree of sequence identity with the corresponding target sequence to enhance the probability of homologous recombination. The integration element can be any sequence that is homologous to the target sequence in the host cell genome. In addition, the integration element can be a non-coding or encoding polynucleotide. On the other hand, the vector can be integrated into the genome of the recombinant cell by non-homologous recombination. For autonomous replication, the vector can further include a replication origin that enables the vector to replicate autonomously in the recombinant cell. The origin of replication may be any plasmid replicator that mediates autonomous replication, which functions in the cell. The term "origin of replication" or "plasmid replicator" means a polynucleotide that enables a plasmid or vector to replicate in vivo.
[0063] The polynucleotide of the present application of more than one copy is inserted into a recombinant cell to increase polypeptide production. The increase of the polynucleotide copy number can be obtained by the following method: the sequence of at least one additional copy is integrated into the host cell genome, or the amplifiable selective marker gene includes a polynucleotide, wherein the amplified copy containing the selective marker gene can be selected by culturing cells in the presence of a suitable selection agent, and the cells containing the additional copies of the polynucleotide are thus contained. The method for connecting the above-mentioned elements to construct the recombinant expression vector of the present application is well known to the technical personnel in the art.
[0064] The term "recombinant cell" means any cell type that is susceptible to transformation, transfection, transduction, etc. using a nucleic acid construct or expression vector comprising a polynucleotide of the present application. The term "recombinant cell" encompasses the progeny of any parent cell that has mutations that differ from the parent cell during replication.
[0065] The recombinant cell, which comprises a polynucleotide of the present application, is operably connected to one or more regulatory sequences for instructing the production of the polypeptide of the present application. The construct or vector comprising the polynucleotide is introduced into the recombinant cell so that the construct or vector is maintained as a chromosome as a whole or as a self-replicating extrachromosomal vector as described above. The term "recombinant cell" includes any offspring of the parental cell, which is different from the parental cell due to the mutation occurring during the replication process. The selection of the cell will depend to a great extent on the gene encoding the polypeptide and its source. The recombinant cell can be any cell useful in the recombinant production of the polypeptide of the present application, for example, a prokaryotic or eukaryotic cell.
[0066] The present application provides a long-acting interferon expression strategy, which can achieve a long-acting sustained-release function, and can also be combined with other Fc antigens to make multi-linked multivalent drugs. The specific route is that we use E. coli to express long-acting interferon technology, fuse ProteinAProteinG antibody core binding region at the N-terminus of interferon A2a protein, and place it under a prokaryotic promoter to express the fusion protein in E. coli. The fusion protein can be directly injected into animals after purification to remove endotoxins. Here, the long-acting interferon candidate protein has high therapeutic activity in pigs and can resist the animal's response to porcine blue ear virus infection. Our research results show that animals carrying ProteinAProteinG interferon have the potential to effectively prevent and treat viral infections. This long-acting interferon also has the characteristics of maintaining stability at room temperature in liquids, which can greatly save transportation costs by eliminating the cold chain.
[0067] Collection Instructions
[0068] Classification and nomenclature: Porcine reproductive and respiratory syndrome virus;
[0069] Strain number: PRRSV NADC30;
[0070] Name of depository: General Microbiology Center of China Microbiological Culture Collection Administration;
[0071] Abbreviation of depository unit: CGMCC;
[0072] Address of the depository: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, Postal Code: 100101;
[0073] Deposit date: June 5, 2023;
[0074] The registration number of the Collection Center is: CGMCC No.26423. BRIEF DESCRIPTION OF THE DRAWINGS
[0075] Figure 1 This is a map of the recombinant expression vector PET30-GBPA-porcine interferon 2a.
[0076] Figure 2 This is the electrophoresis result of interferon expressed by Escherichia coli.
[0077] Figure 3 The relationship between induction time and inclusion volume was verified by gel electrophoresis.
[0078] Figure 4 These are the safety observation results of the freeze-dried preparation in rats.
[0079] Figure 5 These are the results of safety observations of the aqueous solution on mice.
[0080] Figure 6 These are the safety observation results of water injection and freeze-dried reconstituted product on piglets.
[0081] Figure 7 This is the result of nucleic acid testing for diarrhea virus. DETAILED DESCRIPTION
[0082] The present application is further described in detail below in conjunction with specific embodiments. The examples given are only for illustrating the present application, not for limiting the scope of the present application. The examples provided below can be used as a guide for further improvements by ordinary technicians in the technical field, and do not constitute a limitation of the present application in any way.
[0083] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.
[0084] The original strain and vector PET30 were provided by the gene synthesis company Qingke Bio. The prokaryotic vector expression gene was optimized according to the Escherichia coli codon. Biochemical reagents: endonuclease and ligase were purchased from TaKaRa, plasmid extraction kit was purchased from Tiangen Bio, Escherichia coli BL21 was purchased from Quanshijin, and other reagents were domestically produced.
[0085] The interferon activity determination method and VSV virus preparation method in the following examples refer to the literature: He Fan et al., "Expression of porcine interferon-γ and safety detection of its antiviral activity" Chin J Biotech 2010, April 25; 26 (4): 439-447 Chinese Journal of Biotechnology ISSN 1000-3061 2010CJB,All rights reserved. The specific steps are as follows:
[0086] 1) Cell preparation: Take well-growing MDCK (NBL-2) cells (Cell Bank of the Chinese Academy of Sciences, catalog number SCSP-5258) and digest them according to the conventional method. Use DMEM (containing double antibodies) containing 100mL / L FBS to prepare cell suspension; count the cells and adjust the cell concentration to 1×10 5 The suspension was then added to a 96-well cell culture plate at 100 μL / well. Incubate at 37°C with 5% CO 2 Culture for 8-10 hours to allow the cells to become a monolayer.
[0087] 2) Add interferon to treat cells: Take the interferon sample to be tested, use DMEM (containing double antibodies) containing 100mL / L FBS to pre-dilute it to a final protein concentration of 0.001mg / mL, then use DMEM (containing double antibodies) containing 100mL / L FBS to perform 10-fold gradient dilution, dilute 6-8 gradients; discard the culture medium in the monolayer cells cultured for 8-10h, add 10-fold dilution of interferon dilution, 100μL per well, add from low concentration to high concentration, and repeat three times for each gradient; at the same time, take 3 wells of virus positive control (no recombinant protein GBPA-interferon 2A, add virus) and 3 wells of negative control (no recombinant protein GBPA-interferon 2A and virus), and add 100μL of DMEM (containing double antibodies) containing 100mL / L FBS to each control well; culture for 12-15h.
[0088] 3) Virus infection: Take VSV virus and dilute it with serum-free DMEM to a final concentration of 1000 TCID 50 / mL; discard the original cell culture medium, wash 2-3 times with sterile PBS, 100μL / well; add 100μL of virus dilution to each well of positive control and interferon-treated cells, and add serum-free DMEM (containing double antibody) culture medium to negative control wells; culture for 24h, observe the results under a microscope after 24h, and take the dilution multiple at which the negative control well has no lesions and the test well has no lesions at all as the antiviral activity unit (IU), such as: 10 -6 Dilution repeated 3 times without lesions, 10 -7 The dilution showed pathological changes, so we set the activity to 1×10 6 (IU) / 0.1ml.
[0089] Example 1. Obtaining GBPA-interferon 2A protein mutant and its encoding gene
[0090] 1.1 Synthesis of coding genes and recombinant expression vectors
[0091] In order to improve the high activity and stability of wild-type interferon, the antibody-binding core protein GBGA and interferon were fused to obtain the recombinant protein GBPA-interferon 2A. The coding gene of the recombinant protein was synthesized according to the codon preference of Escherichia coli by Qingke Biotechnology Co., Ltd., among which the coding gene of the recombinant protein GBPA-interferon 2A was named GBPA-interferon 2a gene, and the gene was constructed into PET30 to obtain the recombinant expression vector PET30-GBPA-porcine interferon 2a, as shown in the map Figure 1 The nucleotide sequence of the recombinant expression vector PET30-GBPA-porcine interferon 2a is SEQ ID No.1.
[0092] The nucleotide sequence of the recombinant protein GBPA-interferon 2A gene is shown in SEQ ID No. 1, 5076-5987, wherein SEQ ID No. 1, 5076-5426 is the N-terminal fusion protein encoding gene of GBGA, 5427-5471 is the GS connecting peptide encoding gene, 5472-5966 is the porcine interferon 2a encoding gene, and 5967-5984 is the His tag encoding gene. The amino acid sequence of the protein encoded by the GBPA-interferon 2A gene is SEQ ID No. 2. SEQ ID No. 2, 1-117 are the amino acid residues of the antibody binding core protein GBGA, 118-132 are the amino acid residues of the GS connecting peptide, 133-297 are the amino acid residues of interferon 2A, and 298-303 are the His tags.
[0093] 1.2. Construction of PET30-GBPA-porcine interferon 2a fusion gene engineering bacteria
[0094] The recombinant vector PET30-GBPA-porcine interferon 2a was transformed into the host bacteria E. coli BL21 (DE3). The specific steps are as follows: take 0.5uL of the recombinant plasmid PET30-GBPA-porcine interferon 2a and add it to the full gold E. coli BL21 (DE3) competent EP tube, ice bath for 30min, heat shock at 42℃ for 90s and ice bath for 2min, add 500uL of non-antibiotic LB, culture at 37℃ for 1 hour, coat the Kana resistance plate, and culture at 37℃ overnight. Pick a single bacterium and inoculate it in LB medium, culture at 37℃, 200rpm shaking for 6 hours, and store the bacterium at -80℃ at a ratio of 7:3 of bacterium liquid: 50% glycerol to obtain the glycerol-stored recombinant strain E. coli BL21 (DE3) / PET30-GBPA-porcine interferon 2a.
[0095] 1.3. Expression of PET30-GBPA-porcine interferon 2a product and determination of expression form
[0096] The recombinant E. coli BL21 (DE3) / PET30-GBPA-porcine interferon 2a stored in glycerol was inoculated into a 250 mL Erlenmeyer flask containing 100 mL LB containing kana resistance at 1% and 1 mm TPTG was added for induction for 7 hours. After induction, the production of products was observed. The results are as follows: Figure 2 , Figure 2 The markers from top to bottom are 120KD-100KD-70KD-50KD-40KD-30KD-25V-14KD, and the induced product has a clear band between the 30-40KD bands. After ultrasonic disruption and centrifugation, the product was found to be expressed in the form of inclusion bodies in the precipitate. The concentration of the product expressed in the form of inclusion bodies increased over time. The results are shown in Figure 3 , 0h, 1h, 2h, 3h, 4h, 5h, 6h, and 7h represent the time of induced expression, respectively. As time goes by, the target protein gradually becomes more concentrated, which is in line with expectations.
[0097] 1.4. Fermentation process of recombinant protein GBPA-interferon 2A
[0098] 1.4.1. High-density fermentation of E. coli in fermenters
[0099] 1.4.1.1. Seed solution preparation or plate culture
[0100] The recombinant strain E. coli BL21 (DE3) / PET30-GBPA-porcine interferon 2a was cultured in LB medium at 30-37°C and 250-280rpm for 10-12 hours. The composition of the LB medium is (by mass ratio): 1% peptone, 0.5% NaCl, 0.5% yeast powder, 25ug / ml kanamycin, and the rest is water.
[0101] 1.4.1.2. Secondary seed preparation
[0102] The recombinant strain E. coli BL21 (DE3) / PET30-GBPA-porcine interferon 2a was cultured in a modified LB medium at 30-37°C and 250-280 rpm for 10-12 hours. The composition of the modified LB medium is (by mass ratio): 0.5% glycerol, 1% peptone, 0.5% NaCL, 0.5% yeast powder, 25ug / ml kanamycin, and the rest is water.
[0103] 1.4.1.3 Fermentation production
[0104] The fermentation culture is carried out in three stages. The fermentation medium is a semi-synthetic medium, and its composition is (g / L): glucose 5, peptone 5, yeast powder 5, KH2PO4 1, K2HPO4 2, Na2HPO4·12H2O 3, (NH4)2SO4 0.2, NH4Cl 0.2, MgSO4·7H2O 0.3, antifoaming agent 0.2, and the solvent is water. The composition of the feeding medium is (g / L): glycerol (glucose) 120, peptone 25, yeast powder 25, MgSO4·7H2O
[0105] 2.5, PTM1 10 ml / L, and the solvent is water. Sterilize at 115 °C for 15 min before use.
[0106] 1.4.1.3.1, Bacterial cell culture stage
[0107] After the fermentation medium is sterilized, add a certain amount of antibiotic (working concentration 25 μg / mL kanamycin) to each liter of the medium, inoculate the seed liquid at 5-10%, and culture with aeration and stirring at 30-37 °C for about 7 hours. During the culture process, as the strain grows, the sugar in the medium is gradually consumed. When the carbon source is consumed, the bacterial cells stop growing and the dissolved oxygen rises. During the culture process, ammonia water is used to maintain the pH value at 7.0.
[0108] 1.4.1.3.2, Carbon source feeding stage
[0109] After confirming that the sugar in the previous step is consumed (taking the rise of DO (dissolved oxygen) by 20% and the rise of pH without adding acid as the standard), start this step. Use feeding to control the dissolved oxygen to be maintained between 10-20%, and maintain 0.15 < u < 0.2 (u is the cell growth rate). Use ammonia water to maintain the pH value at 7.0. This step can be maintained for 2-6 hours before induction.
[0110] 1.4.1.3.3, Induced expression stage
[0111] Start induction 3 hours after feeding. Add 0.1 mM IPTG and induce for 6 hours. Use feeding to control DO between 10-30. During the whole induction process, ammonia water is used to maintain the pH value at 7.0.
[0112] 1.5, Purification of recombinant protein GBPA-interferon 2A
[0113] The fermented broth was centrifuged at 5000-8000rpm for 5-10min to collect the cells and stored at -20°C. A 10% amount was suspended in a buffered lysis liquid and homogenized under high pressure in an ice bath to break the cells, centrifuged at 10000-15000rpm for 20min to separate the precipitate, and resuspended with buffer 1. The precipitate was centrifuged at 10000-15000rpm for 20min to separate the precipitate, resuspended with buffer 2, centrifuged at 10000-15000rpm for 20min to separate the precipitate, resuspended with buffer 3, and centrifuged at 10000-15000rpm for 20min to separate the precipitate, thus obtaining the crude inclusion body.
[0114] Since the inclusion bodies formed by the recombinant protein GBPA-interferon 2A in the bacteria are relatively tight, 8M urea PB buffer (pH 8.0) was used to dissolve the inclusion bodies during the experiment. Inclusion body denaturation liquid was obtained. Finally, the denaturation liquid was diluted and dissolved in the refolding liquid at 4°C overnight to obtain the recombinant protein GBPA-interferon 2A.
[0115] The composition of the buffered lysis solution is: 10 mM Tris-HCl, 200 mM NaCl, 2 mM EDTA, 0.02% lysozyme, and the rest is water, pH 8.0;
[0116] The composition of buffer 1 is: 20 mM PBS + Triton, the solvent is water;
[0117] The composition of buffer 2 is: 2 M urea, 1 mM EDTA, and the solvent is water;
[0118] The composition of buffer 3 is: 1M NaCl, 1mM EDTA), the solvent is water;
[0119] The composition of the refolding solution is: 20 mM Tris-HCl, 1 mM EDTA-Na2, 200 mM β-mercaptoethanol, 10% glycerol (mass ratio), and the rest is water, pH 8.0.
[0120] Example 2: Preparation of long-acting interferon 2A drug
[0121] One or more components such as preservative (mercuric thiosulfate), protein protection solution (glucose or mannitol), stabilizer (NP40 or Tween 20) are mixed with the isolated and purified recombinant protein GBPA-interferon 2A, and the pH value of the mixture is adjusted to pH 7.0-7.5, wherein the concentration of the active ingredient of GBPA-interferon 2A protein is 1×10 protein activity per dose. 5 IU / mL. The specific steps are as follows.
[0122] 2.1. Preparation of aqueous solution
[0123] 2.1.1 Preparation of semi-finished aqueous solution
[0124] Combined with the addition of GBPA-IFN2A attenuation in production, drug formulation design was carried out to prepare three batches of products (batch numbers were A20210425, A20210426 and A20210513). The three batches of GBPA1-IFN2A antigen were prepared with PBS (0.04 mol / L, pH 7.6) to prepare an activity of 1×10 5 IU / mL (determined by vsv method) aqueous solution.
[0125] 2.1.2. Preparation of finished aqueous solution
[0126] The aqueous solution is packaged into ampoules with a specification of 5 mL / bottle. According to different batch numbers, they are numbered as YGBPA-interferon 2A-1, YGBPA-interferon 2A-2, and YGBPA-interferon 2A-3, and 100 vials are prepared for each number.
[0127] 2.2 Preparation of lyophilized preparations
[0128] 2.2.1 Preparation of semi-finished lyophilized preparation
[0129] The freeze-drying machine is LYO-05 Dongfulong, and the freeze-drying conditions are as follows: freezing control: -47℃ for 180 minutes. Primary sublimation: -8℃ set for 120 minutes, lasting for 1200 minutes, vacuum 8pa. Analytical drying: 26℃ set for 60 minutes, lasting for 120 minutes, vacuum 12pa; 25℃ set for 10 minutes, lasting for 180 minutes, vacuum 0pa. Among them, the aqueous phase is the GBPA1-interferon 2A semi-finished aqueous solution prepared in 2.1.1, and the protective agent is a 100g / L mannitol aqueous solution.
[0130] 2.2.2 Preparation of lyophilized finished product
[0131] The semi-finished lyophilized preparation prepared in 2.2.1 was divided into ampoules, and three batches of GBPA1-IFN2A antigen were prepared into ampoules with an activity of 1×10 5 IU / mL, 2 ml per bottle for freeze drying. According to different batch numbers, they are numbered as GGBPA-interferon 2A-1, GGBPA-interferon 2A-2, GGBPA-interferon 2A-3, and 100 vials are prepared for each number.
[0132] 2.3. Semi-finished product inspection method
[0133] 2.3.1. Protein content determination
[0134] The protein content was detected according to the Coomassie Brilliant Blue method.
[0135] 2.3.2 Sterility test
[0136] All protein solutions are sterile filtered and tested according to the current method in the appendix of the Chinese Pharmacopoeia of Veterinary Medicine, and there should be no sterile growth.
[0137] 2.3.3 Finished product inspection
[0138] 1) Properties
[0139] Appearance of aqueous solution: Visually observe that the test drug should remain a colorless, clear liquid without flocculent impurities when packaged.
[0140] Appearance of lyophilized agent: The lyophilized agent should be complete and free of shrinkage bubbles.
[0141] 2) Sterility test
[0142] Test according to the appendix of the current Chinese Pharmacopoeia of Veterinary Medicine.
[0143] 3) Endotoxin content
[0144] Randomly sample one bottle of the protein to be tested, collect the aqueous phase and mix it thoroughly, and test it according to the bacterial endotoxin test method in the appendix of the current "Chinese Pharmacopoeia of Veterinary Medicine". The protein endotoxin should not be greater than 5EU / mL.
[0145] 2.3.4 Experimental results are shown in Table 1
[0146] Table 1 Results of quality inspection
[0147] Source batch number Sterility testing Endotoxin content / mL Total protein content / mL determination A20210425 Sterile Normal 2.44EU 29.16mg Meet quality standards A20210426 Sterile Normal 0.89EU 25.83mg Meet quality standards A20210513 Sterile Normal 1.95EU 35.24mg Meet quality standards
[0148] Example 3, GBPA-interferon 2A safety experiment
[0149] 3.1 Materials
[0150] Test protein: water-based YGBPA-interferon 2A-1, YGBPA-interferon 2A-2, YGBPA-interferon 2A-3 and lyophilized GGBPA-interferon 2A-1, GGBPA-interferon 2A-2, GGBPA-interferon 2A-3. The lyophilized samples were diluted with sterile water according to their activity to ensure an activity of 1×10 5 IU / mL.
[0151] Experimental animals: 2 guinea pigs weighing 350-400 g; 5 SPF-grade female C57BL / 6 mice weighing about 25 g (purchased from Beijing Huafukang Biotechnology Co., Ltd.), all purchased by Huaxia Xingyang Technology Co., Ltd.; 2 healthy susceptible piglets aged 1-10 days, purchased from a farm in Tangshan of a three-way hybrid breed (Duroc boar as the sire, and hybrid sows selected from the cross between Landrace boar and Large White sow as the dam for mating).
[0152] 3.2 Methods and Results
[0153] 1) Testing with guinea pigs and mice
[0154] Five rats weighing 200-350g were subcutaneously injected with 1mL of the aqueous solution; five mice weighing 18-22g were subcutaneously injected with 0.5mL of the interferon preparation drug dissolved in 2mL of the lyophilized agent. After 7 consecutive days of observation, no death or obvious local or systemic adverse reactions caused by the injection of interferon protein should occur. The results are shown in Table 2.
[0155] 2) Testing with pigs
[0156] Ten healthy susceptible piglets aged 30-40 days were used, and 1 mL of aqueous solution and 1 mL of lyophilized solution were injected into the muscles behind the ears on both sides and observed for 14 days. No abnormal reactions caused by interferon should occur. The safety test results of different batches and dosage forms of interferon on mice, rats and piglets are shown in Table 2.
[0157] Table 2 Safety test results (healthy / total number)
[0158] Protein No. Rat Mouse Piglets YGBPA-IFN2A-1 5 / 5 5 / 5 10 / 10 YGBPA-IFN2A-2 5 / 5 5 / 5 10 / 10 YGBPA-IFN2A-3 5 / 5 5 / 5 10 / 10 GGBPA-IFN2A-1 5 / 5 5 / 5 10 / 10 GGBPA-IFN2A-2 5 / 5 5 / 5 10 / 10 GGBPA-IFN2A-3 5 / 5 5 / 5 10 / 10
[0159] The results showed that all animals injected with interferon were alive and well, with no deaths, no obvious local adverse reactions or systemic reactions, and no obvious swelling and ulceration caused by protein injection. Figure 4 Figure 5 Figure 6 This proves that the interferon prepared in this application has passed the safety verification.
[0160] Example 4: Study on the protection of 30 strains of blue ear in piglets by interferon
[0161] 4.1 Materials
[0162] Experimental pigs: 11 three-way piglets aged 21-28 days (purchased from a farm in Tangshan), and the experiments were all conducted in the animal room of Huaxia Xingyang Company.
[0163] The attacking virus strain: Porcine reproductive and respiratory syndrome virus (commonly known as porcine blue ear virus), number: PRRSV NADC30.
[0164] 4.2 Methods
[0165] The experiment was carried out in groups according to the protection scheme in Table 3.
[0166] Table 3 Application effect test on porcine blue ear virus disease
[0167]
[0168] Collection indicators:
[0169] Body temperature was measured daily after virus infection, and the day of virus injection for the treatment and control groups was recorded as D1.
[0170] Blood was collected on D3, D7, D11 and D18 to detect viremia; RNA was extracted using a column extraction kit (Tian Gen; DP304-03), and transcribed using a one-step taq enzyme (TAKARA product number RR055A). The primers used were: PRRST1: 5'-ATGGGCGACAATGTCCCTAAC-3'PRRST2: 5'-ggggaaagcctcatattccgtctg-3, and the amplification system conditions are shown in Table 4:
[0171] Table 4 RT-PCR reaction solution system and amplification conditions
[0172]
[0173] 4.3 Experimental Results
[0174] Record the piglets' clinical symptoms, mental state, diet and other feeding conditions.
[0175] The results showed that the piglets in the prevention group were given drugs for 3 consecutive days before being infected with PRRS virus. On the 4th day after being infected with PRRS virus, the piglets showed obvious fever and obvious symptoms. The virus could be detected from the 3rd day, but the virus was gradually cleared over time and the body temperature gradually returned to normal, as shown in Table 5 and Table 6. The piglets in the treatment group were given drugs for 5 consecutive days after being infected with PRRS virus. The piglets showed normal clinical manifestations within 5 days of drug administration, abnormal body temperature and mild diarrhea within 5 days of treatment, and the virus blood test was negative on the 7th day. The control group showed obvious fever on the 1st day after the virus was challenged, and the piglets had obvious symptoms such as diarrhea and weight loss, and the virus blood test was positive on the 3rd day.
[0176] Conclusion: Interferon has a preventive effect on blue ear virus, which is manifested in that prevention for 3 days can resist the strong blue ear virus attack, and interferon treatment after the attack can quickly eliminate the virus within 5 days.
[0177] Table 5 Results of the test on the effect of recombinant interferon on porcine blue ear virus
[0178]
[0179] Table 6 Results of the test on the effect of recombinant interferon on porcine blue ear virus
[0180]
[0181] The present application has been described in detail above. For those skilled in the art, without departing from the purpose and scope of the present application, and without the need to carry out unnecessary experimental conditions, the present application can be implemented in a wide range under equivalent parameters, concentrations and conditions. Although the present application provides specific embodiments, it should be understood that further improvements can be made to the present application. In a word, according to the principles of the present application, the present application is intended to include any changes, uses or improvements to the present application, including departure from the disclosed scope in the present application and changes made with conventional techniques known in the art.
Claims
1. Protein, Features: The protein is a fusion protein GBPA-interferon 2A, and the fusion protein GBPA-interferon 2A is formed by fusion of protein A and protein B. The protein A is any one of the following A1)-A3): A1), a protein having an amino acid sequence of positions 1 to 117 of SEQ ID No. 2; A2) A protein obtained by substitution and / or deletion and / or addition of amino acid residues in the amino acid sequence shown in A1), which has more than 80% identity with the protein shown in A1) and is related to the antibody binding core protein GBGA; A3), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A1) or A2); The protein B is any one of the following A4)-A6): A4), a protein having an amino acid sequence of positions 133-297 of SEQ ID No. 2; A5) A protein obtained by substitution and / or deletion and / or addition of amino acid residues in the amino acid sequence shown in A4), which has more than 80% identity with the protein shown in A4) and is related to porcine interferon; A6), a fusion protein obtained by connecting a tag to the N-terminus and / or C-terminus of A5) or A6).
2. Nucleic acid molecules, Features: The nucleic acid molecule encodes the fusion protein GBPA-interferon 2A described in claim 1, and the nucleic acid molecule is any one of the following g1)-g3), g1), the coding sequence of the coding strand is the DNA molecule shown in positions 5076-5987 of SEQ ID No.1; g2), a DNA molecule that has 80% or more identity with the nucleotide sequence defined in g1), and encodes the fusion protein GBPA-interferon 2A described in claim 1.
3. Expression cassette, Features: The expression cassette contains the nucleic acid molecule of claim 2.
4. Recombinant vector, Features: The recombinant vector contains the nucleic acid molecule according to claim 2 or the expression cassette according to claim 3.
5. Recombinant microorganisms, Features: The recombinant microorganism contains the nucleic acid molecule according to claim 2 or the expression cassette according to claim 3 or the recombinant vector according to claim 4.
6. Recombinant transgenic cell lines, Features: The recombinant transgenic cell line contains the nucleic acid molecule according to claim 2 or the expression cassette according to claim 3 or the recombinant vector according to claim 4.
7. A medicine containing the protein according to claim 1.
8. A method for preparing the protein according to claim 1, include: The step of expressing the coding gene of the fusion protein GBPA-interferon 2A in claim 1 in biological cells to obtain the protein in claim 1; the organism is a microorganism, a plant or a non-human animal.
9. The method according to claim 8, Features: The biological cells are non-human mammalian cells.
10. Application, Features: The application is any of the following: P1), use of the protein according to claim 1 in the preparation of drugs for preventing and / or treating porcine viral diseases or antiviral drugs or antiviral infection drugs; P2) Use of the nucleic acid molecule according to claim 2 in the preparation of drugs for preventing and / or treating porcine viral diseases or antiviral drugs or antiviral infection drugs; P3) Use of the expression cassette according to claim 3 in the preparation of drugs for preventing and / or treating porcine viral diseases or antiviral drugs or antiviral infection drugs; P4), use of the recombinant vector according to claim 4 in the preparation of drugs for preventing and / or treating porcine viral diseases or antiviral drugs or antiviral infection drugs; P5) Use of the recombinant microorganism according to claim 5 in the preparation of drugs for preventing and / or treating porcine viral diseases or antiviral drugs or antiviral infection drugs; P6) Use of the recombinant transgenic cell line according to claim 6 in the preparation of drugs for preventing and / or treating porcine viral diseases or antiviral drugs or antiviral infection drugs.
